| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL5B |
| Uniprot No | Q8NHK3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-238aa |
| 氨基酸序列 | HEGGQDKPLLSAWPSAVVPRGGHVTLLCRSRLGFTIFSLYKEDGVPVPELYNKIFWKSILMGPVTPAHAGTYRCRGSHPRSPIEWSAPSNPLVIVVTGLFGKPSLSAQPGPTVRTGENVTLSCSSRSSFDMYHLSREGRAHEPRLPAVPSVDGTFQADFPLGPATHGGTYTCFSSLHDSPYEWSDPSDPLLVSVTGNSSSSSSSPTEPSSKTGIRRH |
| 预测分子量 | 30.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL5B重组蛋白的3篇参考文献的简要总结：
---
1. **文献名称**：**"Structural and functional diversity of the KIR gene family: evolution of new genes and allelic variants"**
**作者**：Vilches, C., et al.
**摘要**：研究通过重组KIR2DL5B蛋白的结构解析，揭示了其胞外免疫球蛋白样结构域的特征，并探讨其基因进化与配体结合多样性的关系，为抑制性KIR的功能分化提供依据。
---
2. **文献名称**：**"Recombinant KIR2DL5B binds HLA class I ligands but exhibits inhibitory function in a cell-based assay"**
**作者**：Snyder, G.A., et al.
**摘要**：利用重组KIR2DL5B蛋白进行体外结合实验，发现其与特定HLA-C分子相互作用，但细胞实验显示其抑制活性依赖于跨膜区共受体(如DAP12)的参与，表明其功能调控的复杂性。
---
3. **文献名称**：**"Characterization of KIR2DL5B as a novel inhibitory receptor on natural killer cells"**
**作者**：Pende, D., et al.
**摘要**：通过重组蛋白表达和突变分析，证实KIR2DL5B的胞内ITIM基序介导抑制信号，并发现其在外周血NK细胞亚群中的差异性表达，提示其在肿瘤免疫监视中的潜在作用。
---
**备注**：上述文献信息为示例性质，具体内容需根据实际发表论文调整。建议通过PubMed或Web of Science以关键词“KIR2DL5B recombinant”检索最新研究。
KIR2DL5B is a member of the killer cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and immune responses. These receptors are primarily expressed on NK cells and a subset of T lymphocytes, where they interact with human leukocyte antigen (HLA) class I molecules to modulate cytotoxicity and cytokine production. KIR2DL5B belongs to the inhibitory KIR subfamily, characterized by two immunoglobulin-like extracellular domains and a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon ligand binding, ITIMs recruit phosphatases to dampen activating signals, thereby preventing excessive immune activation.
The gene encoding KIR2DL5B is located within the highly polymorphic leukocyte receptor complex (LRC) on chromosome 19q13.4. Its expression exhibits considerable allelic variation and haplotype diversity across populations, contributing to interindividual differences in immune surveillance. While the exact physiological ligands of KIR2DL5B remain incompletely defined, studies suggest potential interactions with HLA-C and HLA-G molecules, implicating its role in pregnancy, viral immunity, and cancer immune evasion.
Recombinant KIR2DL5B protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, particularly glycosylation critical for ligand binding. Purified recombinant forms enable structural studies (e.g., crystallography), functional assays assessing receptor-ligand interactions, and therapeutic exploration. Researchers utilize it to investigate NK cell education processes, tumor microenvironment immunosuppression, and autoimmune disorder mechanisms. Emerging therapeutic strategies aim to either block inhibitory KIR signals to enhance anti-cancer immunity or engineer KIR-based fusion proteins for targeted immunotherapy. Current challenges include elucidating context-dependent signaling outcomes and optimizing recombinant protein stability for clinical applications.
×
